Touchlight Showcases mbDNA Platform in Non-Viral T-Cell Delivery Collaboration at ASGCT 2026

A LinkedIn post from Touchlight highlights the company’s planned participation in the ASGCT 2026 conference, where it will present on novel lipid-based formulations for delivering cell-free single-stranded DNA (mbDNA™) to improve HDR knock-in in primary human T cells. The session is scheduled for Wednesday, 13 May, from 9:30 to 9:45 a.m., and will feature Dr. Peter Archibald of Touchlight and Dr. Claire Guéguen of Sartorius.

The post suggests that Touchlight is positioning its mbDNA™ platform alongside Sartorius’ non-viral delivery solutions as a potential enabler of more efficient gene editing in T cells. For investors, this visibility at a major gene therapy meeting may indicate continued R&D progress and potential for future partnerships or licensing, which could enhance Touchlight’s standing in the cell and gene therapy manufacturing ecosystem.